A ZAG-S&W Team represented Cellect Biotechnology Ltd. (NASDAQ:APOP) (NASDAQ:APOPW) (TASE:CLBD), a developer of innovative technology that enables the functional selection of stem cells, in its initial public offering in the United States of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs.
The gross proceeds to Cellect from this offering are $8.4 million. Cellect's ADSs and warrants began trading on the NASDAQ Capital Market on July 29, 2016, under the symbols "APOP" and "APOPW", respectively.
Cellect plans to use the net proceeds from the offering to fund its ongoing development plan, including its Phase I/II single arm, open label clinical trial and for working capital and other general corporate purposes.
The ZAG-S&W Team included Oded Har-Even, Howard Berkenblit, Shy Baranov and Ron Ben-Bassat.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the sole book runner and Joseph Gunnar & Co., LLC acted as co-manager for the offering.
ZAG-S&W is the world's only true Israeli-American law firm committed to the success of Israeli and U.S. companies seeking to do business between each other's countries. Founded in 2001 through a unique joint venture of its founding firms, Zysman, Aharoni, Gayer & Co. (ZAG) and Sullivan & Worcester LLP (S&W), ZAG-S&W is a law firm partnership—one entity—not a referral relationship. Our innovative business model enables us to provide completely integrated, cost-efficient legal services, leveraging our experience on both sides of the Atlantic to help advance your objectives with maximum efficiency—whether it's forming a joint venture or listing your company on NASDAQ. But we do more than just provide legal services; we build business bridges for our clients, connecting them with the right players and the right resources to gain a competitive edge.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.